Literature DB >> 3872294

Characterization of the plasmid-mediated beta-lactamase in Branhamella catarrhalis, with special reference to substrate affinity.

I Eliasson, C Kamme.   

Abstract

The plasmid-mediated Branhamella catarrhalis beta-lactamase BRO-1, also found in Moraxella nonliquefaciens, was characterized as regards substrate profile, isoelectric point and relative substrate affinity index (RSAI) to various substrates and compared in these aspects with the TEM-1 enzyme of Haemophilus influenzae. As measured by a biological assay and with high performance liquid chromatography (HPLC), BRO-1 was found to hydrolyse carbenicillin, mecillinam, methicillin and cefaclor with a higher rate than TEM-1. The only substrates having a relative rate of hydrolysis higher for TEM-1 than for BRO-1 were ampicillin and cephaloridine. The rates of hydrolysis registered with these two methods were comparable for all but 2 of 13 tested substrates. Isoelectric focusing yielded a main band at pH 5.6 and several satellite bands consistent with those reported by other authors for Branhamella enzymes having a substrate profile similar to that of BRO-1. A tenfold or higher difference in RSAI between BRO-1 and TEM-1 was recorded for five of the 15 compounds tested. BRO-1 seems to be the most common beta-lactamase in Bran. catarrhalis, irrespective of geographic origin. Its substrate profile, isoelectric pattern and RSAI differ from those of other known plasmid-mediated beta-lactamases described, thus justifying a specific designation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872294     DOI: 10.1093/jac/15.2.139

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Discrimination of extended-spectrum beta-lactamases by a novel nitrocefin competition assay.

Authors:  G A Papanicolaou; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

Review 3.  Beta-lactamase nomenclature.

Authors:  George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Emergence of beta-lactamase producing anaerobic bacteria in the tonsils during penicillin treatment.

Authors:  K Tunér; C E Nord
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

5.  Monoclonal antibodies to TEM-1 plasmid-mediated beta-lactamase.

Authors:  C J Morin; P C Patel; R C Levesque; R Letarte
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

6.  Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis.

Authors:  E E Stobberingh; H J van Eck; A W Houben; C P van Boven
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Authors:  D J Payne; R Cramp; D J Winstanley; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 9.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

10.  Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis.

Authors:  H J Bootsma; H van Dijk; J Verhoef; A Fleer; F R Mooi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.